TY - JOUR
T1 - Using subjective cognitive decline to identify high global amyloid in community-based samples
T2 - A cross-cohort study
AU - Buckley, Rachel F.
AU - Sikkes, Sietske
AU - Villemagne, Victor L.
AU - Mormino, Elizabeth C.
AU - Rabin, Jennifer S.
AU - Burnham, Samantha
AU - Papp, Kathryn V.
AU - Doré, Vincent
AU - Masters, Colin L.
AU - Properzi, Michael J.
AU - Schultz, Aaron P.
AU - Johnson, Keith A.
AU - Rentz, Dorene M.
AU - Sperling, Reisa A.
AU - Amariglio, Rebecca E.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Introduction: We aimed to examine the contribution of subjective cognitive decline (SCD) to reduce the number of β-amyloid (Aβ) positron emission tomography scans required for recruiting Aβ+ clinically normal individuals in clinical trials. Methods: Three independent cohorts (890 clinically normal: 72 yrs ± 6.7; Female: 43.4%; SCD+: 24%; apolipoprotein E [APOE] ε4+: 28.5%; Aβ+: 32%) were used. SCD was dichotomized from one question. Using logistic regression, we classified Aβ+ using the SCD dichotomy, APOEε4, sex, and age. Results: SCD increased odds of Aβ+ by 1.58 relative to non-SCD. Female APOEε4 carriers with SCD exhibited higher odds of Aβ+ (OR = 3.34), whereas male carriers with SCD showed a weaker, opposing effect (OR = 0.37). SCD endorsement reduces the number of Aβ positron emission tomography scans to recruit Aβ+ individuals by 13% and by 9% if APOEε4 status is known. Conclusion: SCD helps to classify those with high Aβ, even beyond the substantial effect of APOE genotype. Collecting SCD is a feasible method for targeting recruitment for those likely on the AD trajectory.
AB - Introduction: We aimed to examine the contribution of subjective cognitive decline (SCD) to reduce the number of β-amyloid (Aβ) positron emission tomography scans required for recruiting Aβ+ clinically normal individuals in clinical trials. Methods: Three independent cohorts (890 clinically normal: 72 yrs ± 6.7; Female: 43.4%; SCD+: 24%; apolipoprotein E [APOE] ε4+: 28.5%; Aβ+: 32%) were used. SCD was dichotomized from one question. Using logistic regression, we classified Aβ+ using the SCD dichotomy, APOEε4, sex, and age. Results: SCD increased odds of Aβ+ by 1.58 relative to non-SCD. Female APOEε4 carriers with SCD exhibited higher odds of Aβ+ (OR = 3.34), whereas male carriers with SCD showed a weaker, opposing effect (OR = 0.37). SCD endorsement reduces the number of Aβ positron emission tomography scans to recruit Aβ+ individuals by 13% and by 9% if APOEε4 status is known. Conclusion: SCD helps to classify those with high Aβ, even beyond the substantial effect of APOE genotype. Collecting SCD is a feasible method for targeting recruitment for those likely on the AD trajectory.
KW - APOEε4
KW - Alzheimer's disease
KW - Amyloid
KW - Subjective cognitive decline
UR - http://www.scopus.com/inward/record.url?scp=85072580706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072580706&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.dadm.2019.08.004
DO - https://doi.org/10.1016/j.dadm.2019.08.004
M3 - Article
C2 - 31673597
SN - 2352-8729
VL - 11
SP - 670
EP - 678
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
ER -
